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Background: Treatment planning of localised prostate cancer remains challenging. Besides conventional parameters, a wealth of
prognostic biomarkers has been proposed so far. None of which, however, have successfully been implemented in a routine
setting so far. The aim of our study was to systematically verify a set of published prognostic markers for prostate cancer.
Methods: Following an in-depth PubMed search, 28 markers were selected that have been proposed as multivariate prognostic
markers for primary prostate cancer. Their prognostic validity was examined in a radical prostatectomy cohort of 238 patients with
a median follow-up of 60 months and biochemical progression as endpoint of the analysis. Immunohistochemical evaluation was
performed using previously published cut-off values, but allowing for optimisation if necessary. Univariate and multivariate Cox
regression were used to determine the prognostic value of biomarkers included in this study.
Results: Despite the application of various cut-offs in the analysis, only four (14%) markers were verified as independently
prognostic (AKT1, stromal AR, EZH2, and PSMA) for PSA relapse following radical prostatectomy.
Conclusions: Apparently, many immunohistochemistry-based studies on prognostic markers seem to be over-optimistic. Codes of
best practice, such as the REMARK guidelines, may facilitate the performance of conclusive and transparent future studies.
The risk assessment and management of therapeutic strategies for
prostate cancer are presently still mainly based on clinical criteria,
for example, patient characteristics, clinical stage, serum PSA, and
histopathological features, in particular, tumour extent and
Gleason score. However, not all low-grade prostate cancers with
a Gleason score less than 7 follow an indolent course, and
carcinomas with a Gleason score of 7 or higher, on the other hand,
may (rarely) present with a rather favourable clinical behaviour.
These discrepancies have become increasingly apparent, particu-
larly following the updated recommendations of the 2005 ISUP
Gleason System (Harlan et al, 2003), therefore emphasising the
pressing need for additional molecular prognostic markers.
Interestingly, the lack of reliable molecular biomarkers for the
risk assessment of prostate cancer stands in sharp contrast to an
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ever-emerging number of proposed marker candidates. With
nearly 2900 PubMed hits for the search term ‘prostate cancer
prognostic marker’ (July 2014), no evidently relevant prognostic
biomarker has made its way into clinical practise (Kristiansen,
2012). This issue clearly stresses the necessity to reflect on the
validity of biomarkers and biomarker development or even some
aspects of our scientific publication culture.
Despite the limitation of immunohistochemistry being an only
semiquantitative technique, it still represents an essential metho-
dological approach for a large fraction of published biomarker
studies. This prompted us to experimentally verify the prognostic
value of a wider range of previously published immunohistochem-
ical prognostic markers for prostate cancer in a representative
monocentric cohort of radical prostatectomy patients.
MATERIALS AND METHODS
Criteria for identification of prognostic markers. In a first step,
prognostic markers for prostate cancer were identified in a
PubMed search (‘prostate cancer prognostic/prognosis immuno-
histochemistry’). Eligibility criteria for study inclusion were: (i)
cohort size—a number of patients 450 in studies using
conventional slides or 4100 for tissue microarray (TMA)-based
studies, (ii) multivariate prognostic value demonstrated in Cox
analysis (Po0.05), and (iii) conclusive immunohistochemistry
protocol and antibody availability. From the pool of resulting
candidates, we obtained 28 markers for validation.
Prostate cancer cohort for validation. The cohort consisted of
238 patients having undergone radical prostatectomy for treatment
of primary prostate cancer between 1999 and 2006 and for which
follow-up data were available. This cohort was compiled as a TMA
as described previously, all tumours were reviewed and graded
according to the ISUP 2005 recommendations (Gerhardt et al,
2011; Mortezavi et al, 2011; Beer et al, 2012; Gerhardt et al, 2012).
Follow-up data were obtained from review of patients’ medical
records. Median follow-up time for all patients was 60 months
(mean 55 months). A biochemical recurrence, defined as a rising
PSA level exceeding 0.1 ngml 1, after having reached a nadir post
surgery, occurred in 111 (46.6%) patients. Median time to PSA
Table 1. Overview of selected prognostic markers for prostate cancer: original studies
Marker
Number of
patients
Type of
cohort Statistical endpoint
Hazard
ratio
P-value
(multivariate)
meanþ /median*
follow-up time
(years)
Reference
(PMID)
ADAM9 198 RPE BCR 1.87 0.04 3.8* 18061337
AKT1 63 RPE BCR 2.12 0.02 6þ 16721361
AKT1 840 RPE BCR, death 2.86 0.027 5.1þ 19417030
ALCAM 91 RPE BCR 2.22 0.057 2.5* 15532095
ALCAM 2390 RPE BCR 0.71 0.02 2.9þ 21683980
AR(nuclear) 551 RPE BCR 2.42 0.004 5.5* 15223964
AR(stromal) 53 RPE DSR 0.13 0.005 4.25þ 15378523
BCL2 94 RPE BCR 3.15 0.03 2.3* 16080576
BCL2 228 WW death 2.14 0.004 11* 17850375
CB1R 372 WW death 2.7 0.006 412 19056257
CD10 2724 RPE BCR 1.1 0.034 2.9þ 19047112
CD24 102 RPE BCR 3.24 0.005 2.6* 14716744
CD138 551 RPE BCR/radiological progression missing 0.051 5.3* 12640657
CRGA 528 RPE BCR 1.66 0.049 3.8* 18392627
CRISP3 945 RPE BCR 1.59 0.007 6* 17634540
E-CADHERIN 104 RPE BCR/clinical progression 2.5 0.019 7.9* 18056176
ER-alpha 106 RPE death 5.24 0.036 6.8þ 17294452
ER-beta 159 RPE BCR missing 0.04 5.4* 11454669
EZH2 226 RPE BCR 3.14 0.05 5.5* 17943722
HDAC2 145 RPE BCR 2.36 0.019 4.2* 18212746
HSP-27 553 WW death 1.5 0.03 7.9þ 19707199
Ki-67 108 RPE BCR/clinical progression 2.48 0.01 5.4þ 8691323
MUC1 225 RPE BCR/clinical progression 2.35 0.0005 8* 14711987
N-CADHERIN 104 RPE BCR/clinical progression 5.6 0.003 7.9* 18056176
NFkB 86 RPE BCR 5.0 0.002 3.6þ 16278667
p21 60 WW/RPE death 6.26 0.023 3.4þ 9712417
p27 161 RPE BCR 2.44 0.014 3.75þ 12629353
p53 705 WW death 1.51 0.03 9.75* 19239456
p53 2514 RPE BCR 1.24 0.034 2.9þ 18552821
PSMA 93 RPE BCR 1.4 0.01 2.8þ 17320151
SPINK1 817 RPE BCR 2.02 0.0004 missing 18538735
Vimentin 287 RPE BCR 2.03 0.049 7þ 19447876
Abbreviations: BCR¼biochemical recurrence; DSR¼disease-specific relapse; RPE¼ radical prostatectomy; WW¼watchful waiting/conservative management. +¼mean, *¼median follow up time.
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relapse was 25 months (interquartile range, 12–46 months); among
men not experiencing progression, the median follow-up was 72
months (interquartile range, 60–96 months). In total, 13.4% of
patients were lost to follow-up in the first 4 years.
The median patient age was 64 years (range 46–75 years). The
pT-category was pT2 in 152 patients (63.8%), pT3 in 76 patients
(31.9%), and pT4 in 10 patients (4.3%). A total of 151 patients
(63.4%) presented with complete surgical resection (R0 resection),
whereas 84 patients (35.3%) had undergone a resection with positive
margins (R1 resection). The Gleason score was o7 in 45 patients
(18.9%), equalled a total score of 7 in 133 patients (55.9%), and was
47 in 60 patients (25.2%). Pre-operative PSA levels ranged from
0.39 ngml 1 to 357 ngml 1 (median 10.5 ngml 1, no data were
available for 11 patients). This study was approved by the Cantonal
Ethics Committee of Zu¨rich (approval number StV 25-2007).
Immunohistochemistry. Automated immunohistochemical stain-
ing was carried out on one of the two technical platforms (Ventana
Medical Systems, Tucson, AZ, USA/Leica Microsystems, Mel-
bourne, Australia). If possible, antibodies were selected according
to the preceding publications. Staining protocols including anti-
body dilution, pretreatment, and technical platform are given in
Supplementary Table S1.
Evaluation of immunoreactivity. Immunohistochemical slides
were evaluated and scored by a single observer (FH) after
instruction and supervision of an experienced genito-urinary
pathologist (GK). Wherever possible, we adopted the scoring
system described in the original publications of the respective
markers. Technical details of scoring (localisation, evaluated
feature, and scoring scale) are given in Supplementary Table S2.
Statistics. SPSS 20 (IBM SPSS, Version 20.0, Armonk, NY, USA)
was used for descriptive statistics. Further data analysis was
performed using the R language for statistical computing, version
3.1.0. The statistical significance level was set at 0.05. To verify the
prognostic value of the selected markers, univariate and multi-
variate Cox proportional hazards regression was applied. Multi-
variate Cox regression was performed with inclusion of the
individual selected markers, Gleason score, log10(pre-OP PSA),
dichotomous pT status (pT1/2 vs pT3/4), margins (R0 vs R1), and
patient age. Additionally, markers were dichotomised using the
web-based tool ‘cut off finder’ (Budczies et al, 2012) and were
analysed using Kaplan–Meier estimates and log rank tests. A post
hoc power analysis of the respective models was performed using
the PASS 2008 software (NCSS, Kaysville, UT, USA).
ADAM9 AKT1 ALCAM AR
BCL-2 CB1R CD10 CD24
CD138 CRISP3 CRGA ECAD
ERa ERb EZH2 HDAC2 HSP27
Ki-67 MUC1 NCAD NFKB
PSMA SPINK1 VIMp21 p27 p53
Figure 1. Immunoreactivity of selected prognostic biomarkers. Representative examples of positive immunostaining are shown for each marker,
highlighting the typical subcellular localisation (magnification 200).
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RESULTS
Characteristics of selected biomarker studies from the literature.
Of the markers matching our inclusion criteria, 27 candidates were
selected, 3 of which (androgen receptor, oestrogen receptor-alpha
and -beta) each yielded two data points (stromal and epithelial
immunoreactivity), resulting in 30 biomarkers for further valida-
tion (Table 1). In the originally published studies, cohorts had a
median size of 225 patients (range 53–2724), the median follow-up
time covered 5.0 years (range 1–12), and the median hazard ratio
for disease progression of the reported biomarkers was 2.42 (range
1.1–7.69; values of markers with hazard ratios o1 have been
included as their reciprocal value). All selected biomarkers play a
role in a broad spectrum of tumour-relevant processes including,
for example, proliferation or apoptosis, cell cycle control, cell
adhesion, or hormone signalling. Most studies (n¼ 23) were based
on radical prostatectomy (RPE) cohorts, four studies described
watchful waiting cohorts, and one study described a mixed
population (RPE and watchful waiting).
Immunohistochemistry and expression of selected markers. For
the markers included in this study, representative examples of
positive immunoreactivity in prostate cancer are shown in
Figure 1. Expression frequencies and cut-off values are illustrated
in Figure 2. We attempted to adopt the cut-off values suggested in
the original studies, but allowed for adjustment (optimisation with
the cut-off finder tool) in order to ease verification.
Associations of biomarkers with clinico-pathological para-
meters. The association of marker expression in prostate cancer
with pT category, Gleason score, and pre-operative serum PSA was
analysed in a Spearman rank correlation analysis. As expected for
independent prognostic markers, most associations failed signifi-
cance, even though some dependencies became apparent, particu-
larly with Gleason score and serum PSA, but high correlation
coefficients were not noted (Supplementary Table S3).
Prognostic significance of putative prognostic biomarkers.
Initially, we conducted a post hoc power analysis and found that
the available sample size of 238 analysable patients on the TMA
would be sufficient to detect clinically relevant hazard ratios at a
significance level of 0.05 and a power of almost 100%
(Supplementary Figure S1).
Kaplan–Meier analyses identified 11 markers as being univariate
significant factors: AR epithelial/stromal, CB1R, CRGA, E-Cad-
herin, EZH2, Ki-67, NFkB, p21, p27, and PSMA (Table 2). In
univariate Cox analyses, only nine markers were found significant
(nuclear and stromal AR, CB1R, CRGA, E-Cadherin, NFkB, p21,
p27, and PSMA), CD10 was of borderline significance (P¼ 0.051)
and Ki-67 dropped out. Multivariate Cox regression, which was
applied to analyse the prognostic value of the markers in
combination with other prognostic factors, demonstrated signifi-
cance for only the four markers AKT1, stromal AR, EZH2, and
PSMA (Table 3). A marker-wise comparison of published and
verified multivariate prognostic value, illustrated by a forest plot,
highlights these differences (Figure 3). In three of the four
confirmed prognostic markers, the verified hazard ratio was lower
than originally reported; only for one (PSMA), a higher hazard
ratio was found.
To further analyse the prognostic values in the clinically relevant
subgroup of tumours with Gleason scores of 6 or 7, another
multivariate model was calculated (Table 4). In this tumour
subgroup, again AKT1, stromal AR, and PSMA and additionally
CB1R, CD10, E-Cadherin, and N-Cadherin were confirmed.
DISCUSSION
The present study is the first to systematically analyse and verify a
larger set of proposed prognostic immunohistochemical markers
for prostate cancer that have been demonstrated to be multi-
variate significant predictors for disease progression in previous
ADAM9
AKT1 *
*
*
*
*
*
ALCAM
AR (nuclear)
AR (stromal)
BCL2
CB1R
CD10
CD24
CD138
CHRG
CRISP3
ECAD
EZH2
ER-alpha (stroma)
ER-beta (stroma)
ER-beta (epithelium)
HDAC2
HSP27
Ki-67/MIB1
MUC1
N-CADHERIN
NFkB
p21
p27
p53
PSMA
SPINK1
Vimentin
0% 20% 40% 60% 80% 100%
Negative
Weakly positive
Moderately positive
Strongly positive
ND
ER-alpha (epithelium)
Figure 2. Frequencies of immunohistochemically detected expression of selected prognostic markers in primary prostate carcinomas. Markers
labelled with an asterisk were recorded as immunoreactive scores and summarised for easier visualisation (IRS 0: negative, IRS 1–3: weakly positive,
IRS 4–8 moderately positive, IRS48: strongly positive). Black bars indicate the cut-off used for dichotomising the variable for Cox regression
analysis. Abbreviation: ND: non determined/missing data.
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studies. Although a series of quality criteria needed to be fulfilled
to allow study inclusion, we were unable to confirm the majority
of prognostic markers selected. Only 10 out of 28 markers (35%)
could be verified in a univariate Cox approach and only 4 (14%)
were subsequently confirmed as significant in a multivariate
setting. According to these results, the loss of stromal androgen
receptor expression was the biomarker with the most significant
prognostic impact (hazard ratio 3.33); a finding that doubtlessly
deserves further investigation. This rather remarkable discre-
pancy of published data and this study’s results might be
explained by either significant shortcomings of this verification
study or general deficits in the publication culture concerning
prognostic markers that may be either over-optimistic or too
permissive.
Concerning the former, great care was taken to minimise
potential biases in the conduction of this study. The study cohort,
which comprised 238 primary prostate cancer patients, is a well
established, contemporary, monocentric prostatectomy cohort
which has been extensively used in previous publications
(Tischler et al, 2010; Gerhardt et al, 2011; Mortezavi et al,
2011; Beer et al, 2012; Gerhardt et al, 2012). Although the number
of patients may appear low at first sight, we want to point out,
that it already exceeds the median cohort size of the studies
re-analysed. Further, the application of study cases compiled as
TMA does not only allow for a convenient high-throughput
workflow but also serves as a model of biopsy-detected prostate
cancer. In the present setup, each index tumour is represented by
a single core. Even though this introduces a potential sampling
bias and may compromise the analysis of highly heterogeneously
expressed proteins, it also increases the likelihood to identify
robust clinical prognostic markers, which ought to be detectable
in a single core of a tumour-positive biopsy. Protocols for
immunohistochemistry were adapted as closely to the original
protocols as possible, and immunohistochemical staining was
performed on standardised automated platforms that are also
used for routine diagnostics at the Institute of Surgical Pathology
of the University Hospital Zurich. To minimise interobserver
variability, a single observer evaluated all slides. Our attitude
towards statistical marker verification was deliberately benevo-
lent, allowing for optimisation of cut-off values. Even when
simplifying the multivariate model, excluding margins and
patient age, the number of significantly prognostic biomarkers
did not increase (data not shown). However, a caveat to the
validity of the current study is that Ki-67, which is assumedly the
best verified prognostic marker in prostate cancer, only showed a
univariate significance (Kristiansen, 2012; Fisher et al, 2013).
Admittedly, the composition of our study cohort may lead to a
bias, with cases enriched for high-grade and high-stage tumours,
leading to a relapse rate of 46%, which is approximately 15
percentage points above the usual rates of consecutive RPE
cohorts. However, this acknowledged bias should be expected to
ease the verification of biomarker candidates and is therefore
considered useful in this studies’ setting.
The most apparent deficit of the original studies lies in their
study design, which was generally based on a retrospective
analysis of a single cohort. This type of analysis is prone to model
overfitting and is nowadays increasingly regarded as only
hypothesis-generating because the important validation is
missing. A more appropriate approach includes an initial
analysis of a training cohort to establish a test hypothesis and
a cut-off value, which is then verified in an independent testing
cohort. In a way, this study provides the necessary testing cohort
for these studies, even though under considerably tightened
conditions with probable differences in surgery, in the pre-
analytic steps, the immunostaining protocols, and the analytical
attitude of the observers in the interpretation of immunostain-
ings. The impact of correct statistical handling in biomarker
studies has long been recognised and has led to several
recommendations (Harris, 2005; McShane et al, 2005b), most
importantly, the REMARK (‘REporting recommendations for
tumor MARKer prognostic studies’) guidelines (Simon and
Altman, 1994; Hayes et al, 1996; Altman, 1998). These provide a
comprehensive description of quality criteria for prognostic
biomarker studies but are still not widely accepted, as Mallett
et al (2010) recently demonstrated in a meta-analysis; an
observation we can only confirm.
An additional potential bias lies in the composition of the
respective cohort under analysis, which may also influence
biomarker performance (Braun et al, 2011). It remains unclear
whether a biomarker that performs well in clinically detected
populations shows similar performance in a contemporary PSA
screen-detected cohort. Also, a possible influence of patient
ethnicity cannot be excluded. Last but not least, the evolution of
Gleason grading in the last decade (ISUP 2005) may introduce a
significant bias and it is unclear which type of Gleason grading the
individual studies were based on.
A general deficit of most TMA-based studies is the missing
demonstration of relevant construction bias. Ideally, a new TMA
Table 2. Kaplan–Meier analysis of PSA relapse-free survival
for selected prognostic markers following cut-off
optimisation
Marker
Optimal
cut-off
Hazard ratio
(95% CI) P-value
ADAM9 2.5 0.74 (0.36–1.53) 0.41
AKT1 25% 1.65 (0.92–2.95) 0.09
ALCAM 1.5 1.35 (0.89–2.06) 0.16
AR (epithelial) 2.5 0.60 (0.37––0.95) 0.028
AR (stromal) 1.5 0.30 (0.17–0.53) o 0.001
BCL2 30% 1.32 (0.72–2.40) 0.37
CB1R 1.5 1.70 (1.10–2.62) 0.017
CD10 1.5 1.27 (0.86–1.89) 0.22
CD24 1.5 0.71 (0.44–1.15) 0.16
CD138 0.5 1.67 (0.93–2.99) 0.08
CRGA 2.5 2.04 (1.03–4.04) 0.037
CRISP3 0.5 0.76 (0.51–1.14) 0.19
E-CADHERIN 1.5 1.67 (1.13–2.45) 0.009
EZH2 8.5 1.84 (1.20–2.82) 0.004
ER-alpha (Epithelium) n.a.
ER-alpha (Stroma) 0.5 1.34 (0.81–2.23) 0.25
ER-beta (Epithelium) 1.5 1.41(0.73–2.72) 0.3
ER-beta (Stroma) 1.5 0.67 (0.27–1.66) 0.39
HDAC2 8.5 1.35 (0.70–2.61) 0.37
HSP27 1.5 0.73 (0.32–1.66) 0.45
Ki-67/MIB1 6.5% 2.05 (0.99–4.21) 0.047
MUC1 0.5 0.91 (0.62–1.53) 0.61
N-CADHERIN 0.5 0.63 (0.37–1.06) 0.078
NFkB 0.5 2.47 (1.08–5.63) 0.026
p21 2.5% 2.67 (1.48–4.80) 0.00067
p27 2.5 0.58 (0.39–0.86) 0.0064
p53 0.5% 1.33 (0.81–2.18) 0.26
PSMA 1.5 2.56 (1.66–3.94) o0.001
SPINK1 0.5 0.49 (0.18–1.33) 0.15
Vimentin 1.5 1.83 (0.95–3.53) 0.066
Abbreviations: CI¼ confidence interval; n.a.¼ not applicable; PSA¼prostate-specific
antigen.
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should be verified with a panel of established markers prior to the
analysis of new candidates, and this confirmative data should be
included in the Supplementary Material of the first publication.
We further suggest publicising the immunohistochemistry raw
data sets in order to allow re-analyses and insightful meta-
analytic studies. This would allow for proper post-publication
data review and would prospectively increase the quality of
published papers. Even though high-quality journals demand the
deposition of genomic data in centralised repositories, there is no
widely acknowledged infrastructure for immunohistochemistry
data. This may be partly due to the widespread notion of
immunohistochemistry being a somewhat arbitrary technique
yielding semiquantitative results. However, the growing number
of immunohistochemistry-based biomarker studies indicates the
necessity for better tools to increase their quality and to allow for
a better comparison of the published data.
The main restriction of immunohistochemistry as a technique is
missing normalisation. Many factors influence the final signal
intensity, considering differences in pre-analytic steps, section
thickness, antigen retrieval techniques, antibody quality and
concentration, and detection systems. To our knowledge, the
approach of normalising an immunohistochemical staining signal
by simultaneous measurement of a ‘housekeeping protein’ has not
been pursued widely and is a field that needs to be developed in the
future. Certainly, this would necessitate computer-aided image
analysis, which, taken by itself, has not been a major breakthrough
so far (Rizzardi et al, 2012).
The search for molecular prognostic markers for malignant
tumours has been a central aim of biomedical researchers in the
last two decades. A more concise diagnosis provided by a
molecular marker may facilitate individualised patient treatment.
Additionally, prognostic markers might help to unravel the
molecular background of tumour progression and even represent
an attractive new therapeutic target. Ideally, a prognostic factor
only has a few degrees of freedom and allows for a dichotomous
or trichotomous readout (e.g., negative/positive or nil/low/high)
to ensure a high degree of reproducibility. Unfortunately, this
does not exactly hold true for the majority of biomarkers
measured on expression level, which necessitate cut-off values to
delineate meaningful prognostic subgroups. As these cut-off
values are mainly arbitrarily chosen, and the most popular
platform to determine protein expression in tumour tissues is
immunohistochemistry, it does not surprise that the reproduci-
bility of these prognostic markers is limited (Altman et al, 1994).
Table 3. Univariate and multivariate Cox analysis of PSA relapse-free survival for verified prognostic markers
Marker
Univariate hazard
ratio (95% CI) P-value
Multivariate hazard
ratio (95% CI) P-value n
ADAM9 1.03 (0.69–1.52) 0.895 1.07 (0.70–1.62) 0.752 208
AKT1 1.20 (0.78–1.85) 0.412 1.61 (1.01–2.54) 0.043 208
ALCAM 0.72 (0.46–1.13) 0.149 0.85 (0.52–1.38) 0.502 223
AR (nuclear) 0.60 (0.37–0.95) 0.029 0.70 (0.43–1.14) 0.152 193
AR (stromal) 0.30 (0.17–0.53) o0.001 0.32 (0.17–0.59) o 0.001 196
BCL2 1.04 (0.66–1.64) 0.864 0.99 (0.62–1.59) 0.979 220
CB1R 1.70 (1.10–2.62) 0.017 1.45 (0.91–2.31) 0.114 216
CD10 1.55 (1.00–2.40) 0.051 1.27 (0.79–2.05) 0.319 205
CD24 0.71 (0.44–1.15) 0.161 1.08 (0.64–1.82) 0.778 214
CD138 1.20 (0.77–1.88) 0.417 1.08 (0.67–1.75) 0.741 210
CRGA 2.04 (1.03–4.04) 0.042 1.85 (0.91–3.76) 0.089 222
CRISP3 0.76 (0.51–1.14) 0.188 0.71 (0.47–1.09) 0.118 203
E-CADHERIN 1.56 (1.06–2.29) 0.023 1.34 (0.89–2.02) 0.160 212
EZH2 1.27 (0.86–1.87) 0.229 1.48 (0.98–2.23) 0.010 210
ER-alpha (Epithelium) 2.00 (0.87–4.60) 0.100 1.03 (0.44–2.41) 0.953 195
ER-alpha (Stroma) 1.34 (0.81–2.23) 0.256 1.44 (0.81–2.57) 0.218 195
ER-beta (Epithelium) 1.16 (0.74–1.84) 0.515 0.88 (0.54–1.45) 0.624 184
ER-beta (Stroma) 1.16 (0.67–2.02) 0.598 0.83 (0.45–1.51) 0.540 186
HDAC2 1.18 (0.79–1.75) 0.415 0.99 (0.65–1.51) 0.961 205
HSP27 0.81 (0.39–1.67) 0.568 0.77 (0.35–1.70) 0.520 212
Ki-67/MIB1 1.43 (0.80–2.56) 0.226 1.21 (0.64–2.28) 0.552 223
MUC1 1.05 (0.72–1.53) 0.814 0.93 (0.62–1.40) 0.722 224
N-CADHERIN 0.63 (0.37–1.06) 0.080 0.66 (0.38–1.16) 0.149 219
NFkB 2.47 (1.08–5.63) 0.031 2.13 (0.76–5.93) 0.150 222
p21 1.72 (1.15–2.56) 0.008 0.87 (0.54–1.40) 0.556 214
p27 0.58 (0.39–0.86) 0.007 0.73 (0.48–1.11) 0.137 210
p53 1.33 (0.81–2.18) 0.261 1.06 (0.63–1.80) 0.822 224
PSMA 2.56 (1.66–3.94) o 0.001 1.99 (1.24–3.20) 0.005 186
SPINK1 0.73 (0.30–1.80) 0.501 0.80 (0.29–2.20) 0.661 220
Vimentin 1.34 (0.89–2.03) 0.163 1.32 (0.84–2.07) 0.232 209
Abbreviations: CI¼ confidence interval; n.a.¼ not applicable; PSA¼prostate-specific antigen.
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Promising future exceptions could be genetic events of prog-
nostic value, which may be detected with mutation-specific
antibodies. Although it is difficult to overcome the inherent
obstacles of contemporary immunohistochemistry, other bio-
logical platforms may offer a more robust alternative. As an
example, several mRNA expression signatures have been
proposed to predict disease progression and are currently
undergoing intense verification (Cuzick et al, 2011; Karnes
et al, 2013; Wu et al, 2013).
Although most authors of prognostic biomarker studies in
prostate cancer investigate markers for therapy planning at the
biopsy stage, these studies, as exemplified in our selection,
mainly use RPE specimens (and not preoperatively sampled
biopsy material) and analyse disease progression following
radical prostatectomy. The inherent but to our knowledge
unproven assumption is that markers of disease progression
following surgery can also be used upfront to estimate the
tumours’ endogenous aggressiveness; or, in other words, that
predictive markers are also prognostic markers. The distinction of
prognostic markers that estimate the natural course of disease
and predictive markers that estimate the response to therapy is
still often ignored. This aspect should be considered carefully, for
surgery might indeed heal and not only ameliorate the disease.
As the TMPRSS2-ERG translocation illustrates, a biomarker may
well allow prognostication in untreated patients (Demichelis
et al, 2007; Attard et al, 2008) but can still fail to predict
progression following therapy (Minner et al, 2011; Pettersson
et al, 2012). Other markers may work in both settings, as
demonstrated by the cell cycle proliferation signature, proposed
by Cuzick et al (2011).
We are convinced that the final and most crucial step in
verification of a biomarker for therapy planning at the initial
biopsy stage would be a prospective trial in an active surveillance
cohort. A reliable biomarker should then be able to identify
insignificant tumours that can safely be kept under surveillance for
a longer time and do not necessitate active treatment because of the
criteria of tumour progression. Even then, long-term follow-up
data with either cancer-specific death or onset of castration
refractory disease as an endpoint would be highly desirable.
Another open point of discussion is, if the commonly used
surrogate marker of disease progression, PSA relapse, is delineating
a clinically meaningful endpoint, because many patients with a
PSA progression will die of other, non-cancer related causes
(Attard and de Bono, 2009). To complicate the matter, the
definition of PSA progression also varies between studies (Nielsen
and Partin, 2007). It also has to be kept in mind, that it is highly
unlikely that molecular prognostic biomarkers solely can supersede
the clinico-pathological parameters that build the basis of
commonly used nomograms, but are only able to add prognostic
information to these. This is in principle good news for
histopathologists who should strengthen their efforts to provide
even more standardised reports in the future, irrespective of
molecular developments.
In summary, this study sheds some very critical light on
contemporary immunohistochemistry studies that aim to
identify prognostic biomarkers for prostate cancer. Acknowl-
edging the inherent limitations of this comprehensive meta-
analysis and verification study, the majority of published
biomarkers could not be confirmed. This is disappointing but
in excellent concordance with the skeptical view of biostatisti-
cians and may also be true for other tumour entities (Ioannidis,
2005, 2013). We feel that in addition to the suggestions made
above, the REMARK guidelines, which summarise important
cornerstones of biomarker investigations, clearly deserve a wider
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reception, better acknowledgment, and stricter adherence in
order to increase the quality of published data in the future
(McShane et al, 2005a).
ACKNOWLEDGEMENTS
We thank Silvia Behnke (immunohistochemistry) and Martina
Storz (TMA facility) for truly excellent technical support.
REFERENCES
Altman DG (1998) Suboptimal analysis using ’optimal’ cutpoints. Br J Cancer
78(4): 556–557.
Altman DG, Lausen B, Sauerbrei W, Schumacher M (1994) Dangers of using
"optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer
Inst 86(11): 829–835.
Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D,
Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, De Bono JS,
Scardino P, Cuzick J, Cooper CS (2008) Duplication of the fusion
of TMPRSS2 to ERG sequences identifies fatal human prostate cancer.
Oncogene 27(3): 253–263.
Attard G, de Bono JS (2009) Prostate cancer: PSA as an intermediate end
point in clinical trials. Nat Rev Urol 6(9): 473–475.
Beer M, Montani M, Gerhardt J, Wild PJ, Hany TF, Hermanns T, Muntener M,
Kristiansen G (2012) Profiling gastrin-releasing peptide receptor in
prostate tissues: clinical implications and molecular correlates. Prostate
72(3): 318–325.
Braun M, Scheble VJ, Menon R, Scharf G, Wilbertz T, Petersen K, Beschorner C,
Reischl M, Kuefer R, Schilling D, Stenzl A, Kristiansen G, Rubin MA, Fend F,
Perner S (2011) Relevance of cohort design for studying the frequency
of the ERG rearrangement in prostate cancer. Histopathology 58(7):
1028–1036.
Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S,
Denkert C (2012) Cutoff Finder: a comprehensive and straightforward
Web application enabling rapid biomarker cutoff optimization. PLoS One
7(12): e51862.
Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D,
Speights VO, Stankiewicz E, Foster CS, Moller H, Scardino P, Warren JD,
Park J, Younus A, Flake 2nd DD, Wagner S, Gutin A, Lanchbury JS, Stone S
(2011) Prognostic value of an RNA expression signature derived from cell
cycle proliferation genes in patients with prostate cancer: a retrospective
study. Lancet Oncol 12(3): 245–255.
Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, Hoshida Y,
Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW,
Andersson SO, Chinnaiyan AM, Johansson JE, Rubin MA (2007)
TMPRSS2:ERG gene fusion associated with lethal prostate cancer
in a watchful waiting cohort. Oncogene 26(31): 4596–4599.
Fisher G, Yang ZH, Kudahetti S, Moller H, Scardino P, Cuzick J, Berney DM
(2013) Prognostic value of Ki-67 for prostate cancer death in a
conservatively managed cohort. Br J Cancer 108(2): 271–277.
Gerhardt J, Montani M, Wild P, Beer M, Huber F, Hermanns T, Muntener M,
Kristiansen G (2012) FOXA1 promotes tumor progression in prostate
cancer and represents a novel hallmark of castration-resistant prostate
cancer. Am J Pathol 180(2): 848–861.
Gerhardt J, Steinbrech C, Buchi O, Behnke S, Bohnert A, Fritzsche F,
Liewen H, Stenner F, Wild P, Hermanns T, Muntener M, Dietel M,
Jung K, Stephan C, Kristiansen G (2011) The androgen-regulated
Calcium-Activated Nucleotidase 1 (CANT1) is commonly overexpressed
in prostate cancer and is tumor-biologically relevant in vitro. Am J Pathol
178(4): 1847–1860.
Harlan SR, Cooperberg MR, Elkin E, Lubeck DP, Meng M, Mehta SS,
Carroll PR (2003) Time trends and characteristics of men choosing
watchful waiting for initial treatment of localized prostate cancer:
results from CaPSURE. J Urol 170(5): 1804–1807.
Harris AL (2005) REporting recommendations for tumour MARKer
prognostic studies (REMARK). Br J Cancer 93(4): 385–386.
Hayes DF, Bast RC, Desch CE, Fritsche Jr. H, Kemeny NE, Jessup JM,
Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ
(1996) Tumor marker utility grading system: a framework to evaluate
clinical utility of tumor markers. J Natl Cancer Inst 88(20): 1456–1466.
Ioannidis JP (2005) Why most published research findings are false. PLoS Med
2(8): e124.
Ioannidis JP (2013) Biomarker failures. Clin Chem 59(1): 202–204.
Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, Crisan A,
Erho N, Vergara IA, Lam LL, Carlson R, Thompson DJ, Haddad Z,
Zimmermann B, Sierocinski T, Triche TJ, Kollmeyer T, Ballman KV,
Black PC, Klee GG, Jenkins RB (2013) Validation of a genomic classifier
that predicts metastasis following radical prostatectomy in an at risk
patient population. J Urol 190(6): 2047–2053.
Kristiansen G (2012) Diagnostic and prognostic molecular biomarkers for
prostate cancer. Histopathology 60(1): 125–141.
Mallett S, Timmer A, Sauerbrei W, Altman DG (2010) Reporting of
prognostic studies of tumour markers: a review of published articles in
relation to REMARK guidelines. Br J Cancer 102(1): 173–180.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM
(2005a) REporting recommendations for tumor MARKer prognostic
studies (REMARK). Nat Clin Pract Urol 2(8): 416–422.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM
(2005b) Reporting recommendations for tumor marker prognostic studies
(REMARK). J Natl Cancer Inst 97(16): 1180–1184.
Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, Simon R,
Tennstedt P, Muller J, Scholz L, Brase JC, Liu AY, Schluter H, Pantel K,
Table 4.Multivariate Cox analysis of PSA relapse-free survival
for verified prognostic markers in the subgroup of tumours
with Gleason scores o¼7
Marker
Multivariate
hazard ratio
(95% CI) P-value n
ADAM9 1.27 (0.72–2.24) 0.402 154
AKT1 1.94 (1.10–3.42) 0.023 151
ALCAM 1.08 (0.52–2.24) 0.834 163
AR (nuclear) 0.94 (0.51–1.73) 0.840 145
AR (stromal) 0.33 (0.16–0.66) 0.002 148
BCL2 1.67 (0.92–3.04) 0.091 161
CB1R 1.96 (1.09–3.52) 0.025 159
CD10 1.86 (1.01–3.39) 0.045 149
CD24 0.79 (0.43–1.45) 0.443 156
CD138 1.10 (0.59–2.04) 0.770 154
CRGA 2.13 (0.82–5.54) 0.121 163
CRISP3 0.66 (0.38–1.16) 0.150 148
E-CADHERIN 2.42 (1.41–4.15) 0.001 155
EZH2 1.58 (0.92–2.70) 0.096 153
ER-alpha (Epithelium) 1.43 (0.47–4.30) 0.528 143
ER-alpha (Stroma) 1.33 (0.61–2.90) 0.479 143
ER-beta (Epithelium) 1.14 (0.57–2.27) 0.713 134
ER-beta (Stroma) 1.53 (0.74–3.19) 0.255 136
HDAC2 1.27 (0.73–2.21) 0.395 153
HSP27 0.65 (0.20–2.17) 0.488 157
Ki-67/MIB1 1.84 (0.70–4.84) 0.219 164
MUC1 1.11 (0.65–1.90) 0.701 164
N-CADHERIN 0.35 (0.14–0.89) 0.027 161
NFkB 7.15 (0.97–52.55) 0.053 162
p21 1.70 (0.97–2.97) 0.062 158
p27 0.84 (0.49–1.45) 0.536 152
p53 1.45 (0.66–3.19) 0.357 164
PSMA 2.47 (1.27–4.79) 0.008 136
SPINK1 0.34 (0.05–2.54) 0.297 162
Vimentin 1.47 (0.80–2.68) 0.214 151
Abbreviations: CI¼ confidence interval; PSA¼prostate-specific antigen.
Biomarkers in prostate cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.588 147
Schumacher U, Bokemeyer C, Steuber T, Graefen M, Sauter G, Schlomm T
(2011) ERG status is unrelated to PSA recurrence in radically operated
prostate cancer in the absence of antihormonal therapy. Clin Cancer Res
17(18): 5878–5888.
Mortezavi A, Hermanns T, Seifert HH, Baumgartner MK, Provenzano M,
Sulser T, Burger M, Montani M, Ikenberg K, Hofstadter F, Hartmann A,
Jaggi R, Moch H, Kristiansen G, Wild PJ (2011) KPNA2 expression is an
independent adverse predictor of biochemical recurrence after radical
prostatectomy. Clin Cancer Res 17(5): 1111–1121.
Nielsen ME, Partin AW (2007) The impact of definitions of failure on the
interpretation of biochemical recurrence following treatment of clinically
localized prostate cancer. Rev Urol 9(2): 57–62.
Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE,
Kunz L, Penney KL, Ligon AH, Suppan C, Flavin R, Sesso HD, Rider JR,
Sweeney C, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG,
Giovannucci EL, Ding EL, Loda M, Mucci LA (2012) The TMPRSS2:ERG
rearrangement, ERG expression, and prostate cancer outcomes: a cohort study
and meta-analysis. Cancer Epidemiol Biomarkers Prev 21(9): 1497–1509.
Rizzardi AE, Johnson AT, Vogel RI, Pambuccian SE, Henriksen J, Skubitz AP,
Metzger GJ, Schmechel SC (2012) Quantitative comparison of
immunohistochemical staining measured by digital image analysis versus
pathologist visual scoring. Diagnostic pathology 7: 42.
Simon R, Altman DG (1994) Statistical aspects of prognostic factor studies in
oncology. Br J Cancer 69(6): 979–985.
Tischler V, Fritzsche FR, Wild PJ, Stephan C, Seifert HH, Riener MO,
Hermanns T, Mortezavi A, Gerhardt J, Schraml P, Jung K,
Moch H, Soltermann A, Kristiansen G (2010) Periostin is
up-regulated in high grade and high stage prostate cancer.
BMC Cancer 10: 273.
Wu CL, Schroeder BE, Ma XJ, Cutie CJ, Wu S, Salunga R, Zhang Y,
Kattan MW, Schnabel CA, Erlander MG, McDougal WS (2013)
Development and validation of a 32-gene prognostic index for prostate
cancer progression. Proc Natl Acad Sci USA 110(15): 6121–6126.
This work is published under the standard license to publish agree-
ment. After 12 months the work will become freely available and
the license terms will switch to a Creative Commons Attribution-
NonCommercial-Share Alike 3.0 Unported License.
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
BRITISH JOURNAL OF CANCER Biomarkers in prostate cancer
148 www.bjcancer.com |DOI:10.1038/bjc.2014.588
